Abstract
Amino acid metabolism plays a crucial role in cancer progression and invasion by modulating immune responses within the tumor microenvironment and tumor immune response. Transmembrane transport of cellular amino acids is mediated by members of the cationic amino acid transporters SLC7 family, a group of cationic amino acid transporters. Dysregulation of SLC7 family genes can disrupt systemic homeostasis, contributing to a variety of diseases, including multiple cancer types. Additionally, SLC7 family members can alter amino acid metabolic plasticity, further influencing tumor adaptation and progression. However, the precise impact of SLC7 family genes within the cancer microenvironment remains largely unexplored. This study analyzed the expression patterns, genomic alterations (single nucleotide variants, copy number variations, methylation levels), pathway activations, and clinical and subtype associations of SLC7 family genes across The Cancer Genome Atlas (TCGA) pan-cancer cohort. SLC7 activity was quantified using the ssGSEA function of the “GSVA” package to generate the SLC7 score, which was found to correlate with oncogenic and immune-related pathways, including mTORC1 signaling, interferon-gamma response, and inflammatory pathways. In vitro validation was conducted using multiple cancer cell lines (A549, H1299, HCT116, FaDu, Panc-1) and counterparts (BxPC-3, SW480, H460, BEAS-2B, FHC, HaCaT). Gene knockdown was achieved by siRNA transfection, followed by quantitative PCR, Western blotting, and functional assays assessing proliferation, invasion, and ferroptosis (iron and GSH levels) under erastin treatment. SLC7 family genes showed significant associations with immune infiltration and poor prognosis across various cancers. The SLC7 score demonstrated strong positive correlations with malignant and immune-related pathways, such as mTORC1 signaling, interferon-gamma response, and inflammatory response across the pan-cancer cohort. Elevated SLC7 scores were also associated with enhanced immune-related characteristics, and SLC7 genes, particularly SLC7A8 and SLC7A9, emerged as promising predictive markers for response to immune checkpoint inhibitor therapy (Atezolizumab) in cancer patients. Among SLC7 family genes, SLC7A5 expression was markedly elevated in KRAS-mutant tumor cell lines and was required for KRAS-driven proliferation and invasion. SLC7A11 was highly expressed in multiple tumor types and protected cancer cells from ferroptosis by maintaining intracellular cystine uptake and redox homeostasis. Individuals exhibiting elevated SLC7 scores and aberrant expression of SLC7 family genes demonstrate significant immune-inflammatory tumor immune microenvironment (TIME) characteristics and predictive potential for immunotherapy. Thus, the SLC7 family genes have the potential to serve as valuable biomarkers and therapeutic targets for cancer patients.
Data availability
All data on the measured ecosystem variables indicating ecosystem functions that support the findings of this study are included within this paper and its Supplementary Information files.
References
Wang, W. & Zou, W. Amino acids and their transporters in T cell immunity and cancer therapy. Mol. Cell. 80 (3), 384–395 (2020).
Jungnickel, K. E. J., Parker, J. L. & Newstead, S. Structural basis for amino acid transport by the CAT family of SLC7 transporters. Nat. Commun. 9 (1), 550 (2018).
Wu, D. et al. Structural basis for amino acid exchange by a human heteromeric amino acid transporter. Proc. Natl. Acad. Sci. U S A. 117 (35), 21281–21287 (2020).
Verrey, F. et al. CATs and hats: the SLC7 family of amino acid transporters. Pflugers Arch. 447 (5), 532–542 (2004).
Gong, W., Chen, Y. & Zhang, Y. Prognostic and clinical significance of solute carrier family 7 member 1 in ovarian cancer. Transl Cancer Res. 10 (2), 602–612 (2021).
Sun, T. et al. SLC7A2 serves as a potential biomarker and therapeutic target for ovarian cancer. Aging (Albany NY). 12 (13), 13281–13296 (2020).
Xia, S. et al. SLC7A2 deficiency promotes hepatocellular carcinoma progression by enhancing recruitment of myeloid-derived suppressors cells. Cell. Death Dis. 12 (6), 570 (2021).
Lowman, X. H. et al. p53 promotes cancer cell adaptation to glutamine deprivation by upregulating Slc7a3 to increase arginine uptake. Cell. Rep. 26 (11), 3051–3060e4 (2019).
Najumudeen, A. K. et al. The amino acid transporter SLC7A5 is required for efficient growth of KRAS-mutant colorectal cancer. Nat. Genet. 53 (1), 16–26 (2021).
Yan, L. et al. A comprehensive analysis of the diagnostic and prognostic value associated with the SLC7A family members in breast cancer. Gland Surg. 11 (2), 389–411 (2022).
Ji, X. et al. Function of SLC7A7 in T-Cell acute lymphoblastic leukemia. Cell. Physiol. Biochem. 48 (2), 731–740 (2018).
Rotoli, B. M. et al. Downregulation of SLC7A7 triggers an inflammatory phenotype in human macrophages and airway epithelial cells. Front. Immunol. 9, 508 (2018).
Dai, W. et al. SLC7A7 is a prognostic biomarker correlated with immune infiltrates in non-small cell lung cancer. Cancer Cell. Int. 21 (1), 106 (2021).
Zhang, H. & Shi, W. J. Association of three common single nucleotide polymorphisms of SLC7A7 with the development of glioma in a Chinese population. Genet. Mol. Res., 16(2), gmr16029026. https://doi.org/10.4238/gmr16029026 (2017).
Januchowski, R. et al. Microarray-based detection and expression analysis of ABC and SLC transporters in drug-resistant ovarian cancer cell lines. Biomed. Pharmacother. 67 (3), 240–245 (2013).
El Ansari, R. et al. The solute carrier SLC7A8 is a marker of favourable prognosis in ER-positive low proliferative invasive breast cancer. Breast Cancer Res. Treat. 181 (1), 1–12 (2020).
Lang, X. et al. Radiotherapy and immunotherapy promote tumoral lipid oxidation and ferroptosis via synergistic repression of SLC7A11. Cancer Discov. 9 (12), 1673–1685 (2019).
Koppula, P., Zhuang, L. & Gan, B. Cystine transporter SLC7A11/xCT in cancer: ferroptosis, nutrient dependency, and cancer therapy. Protein Cell. 12 (8), 599–620 (2021).
Mukhopadhyay, S. & Kimmelman, A. C. Autophagy is critical for cysteine metabolism in pancreatic cancer through regulation of SLC7A11. Autophagy 17 (6), 1561–1562 (2021).
Pitt, J. M. et al. Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy. Ann. Oncol. 27 (8), 1482–1492 (2016).
Petroni, G. et al. Targeting oncogene and non-oncogene addiction to inflame the tumour microenvironment. Nat. Rev. Drug Discov. 21 (6), 440–462 (2022).
Weiss, H. J. & Angiari, S. Metabolite transporters as regulators of immunity. Metabolites, 10(10), 418. https://doi.org/10.3390/metabo10100418 (2020).
Ren, W. et al. Amino-acid transporters in T-cell activation and differentiation. Cell. Death Dis. 8 (5), e2757 (2017).
Yan, R. et al. Structure of the human LAT1-4F2hc heteromeric amino acid transporter complex. Nature 568 (7750), 127–130 (2019).
Sinclair, L. V. et al. Control of amino-acid transport by antigen receptors coordinates the metabolic reprogramming essential for T cell differentiation. Nat. Immunol. 14 (5), 500–508 (2013).
Nakaya, M. et al. Inflammatory T cell responses rely on amino acid transporter ASCT2 facilitation of glutamine uptake and mTORC1 kinase activation. Immunity 40 (5), 692–705 (2014).
Bronte, V. & Zanovello, P. Regulation of immune responses by L-arginine metabolism. Nat. Rev. Immunol. 5 (8), 641–654 (2005).
Zeng, D. et al. Multi-Omics Immuno-Oncology biological research to Decode tumor microenvironment and signatures. Front. Immunol. 12, 687975 (2021).
Lapuente-Santana, O. et al. Interpretable systems biomarkers predict response to immune-checkpoint inhibitors. Patterns (N Y). 2 (8), 100293 (2021).
Wu, G. et al. The Pan-Cancer landscape of crosstalk between TRP family and tumour microenvironment relevant to prognosis and immunotherapy response. Front. Immunol. 13, 837665 (2022).
Jiang, L. et al. Ferroptosis as a p53-mediated activity during tumour suppression. Nature 520 (7545), 57–62 (2015).
Zhang, Y. et al. BAP1 links metabolic regulation of ferroptosis to tumour suppression. Nat. Cell. Biol. 20 (10), 1181–1192 (2018).
Siska, P. J. & Rathmell, J. C. T cell metabolic fitness in antitumor immunity. Trends Immunol. 36 (4), 257–264 (2015).
Lukey, M. J., Katt, W. P. & Cerione, R. A. Targeting amino acid metabolism for cancer therapy. Drug Discov Today. 22 (5), 796–804 (2017).
O’Sullivan, D. & Pearce, E. L. Targeting T cell metabolism for therapy. Trends Immunol. 36 (2), 71–80 (2015).
Lemos, H. et al. Immune control by amino acid catabolism during tumorigenesis and therapy. Nat. Rev. Cancer. 19 (3), 162–175 (2019).
Johnson, D. E., O’Keefe, R. A. & Grandis, J. R. Targeting the IL-6/JAK/STAT3 signalling axis in cancer. Nat. Rev. Clin. Oncol. 15 (4), 234–248 (2018).
Bonavita, E. et al. Antagonistic inflammatory phenotypes dictate tumor fate and response to immune checkpoint Blockade. Immunity 53 (6), 1215–1229e8 (2020).
Tang, T. et al. Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy. Signal. Transduct. Target. Ther. 6 (1), 72 (2021).
Zhou, Q. et al. Ferroptosis in cancer: from molecular mechanisms to therapeutic strategies. Signal. Transduct. Target. Therapy. 9 (1), 55 (2024).
Kanai, Y. Amino acid transporter LAT1 (SLC7A5) as a molecular target for cancer diagnosis and therapeutics. Pharmacol. Ther. 230, 107964 (2022).
Procaccini, C. et al. Signals of pseudo-starvation unveil the amino acid transporter SLC7A11 as key determinant in the control of Treg cell proliferative potential. Immunity 54 (7), 1543–1560e6 (2021).
Maschalidi, S. et al. Targeting SLC7A11 improves efferocytosis by dendritic cells and wound healing in diabetes. Nature 606 (7915), 776–784 (2022).
Canon, J. et al. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. Nature 575 (7781), 217–223 (2019).
Fedoroff, M. Y. et al. Amino acid transporter LAT1 (SLC7A5) promotes metabolic rewiring in TNBC progression through the L-Trp/QPRT/NAD(+) pathway. J. Exp. Clin. Cancer Res. 44 (1), 190 (2025).
Koppula, P. et al. Amino acid transporter SLC7A11/xCT at the crossroads of regulating redox homeostasis and nutrient dependency of cancer. Cancer Commun. (Lond). 38 (1), 12 (2018).
Funding
This project was supported by the HuNan provincial natural science foundation No 2022JJ70163.
This project was supported the National Natural Science Foundation of China 82403075.
Author information
Authors and Affiliations
Contributions
Gang Peng analyzed the data and drafted the manuscript. Liangqi Jiang performed statistical analysis and conducted the experiments. Hao Peng collected the online data participated in bioinformatics analysis. Yang Li organized the study. Yang Li and Mingrui Li designed the experiments and revised the manuscript, and supervised all analysis. All authors reviewed and proved the final manuscript.
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing interests.
Ethics statement
The study was conducted in accordance with the Declaration of Helsinki, and approved by the Ethics Committee of Xiangya Hospital. (202103708;2021.10.08).
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Peng, G., Peng, H., Shao, Z. et al. Integrative pan-cancer analysis reveals the prognostic and immunological significance of SLC7 family cationic amino acid transporters. Sci Rep (2026). https://doi.org/10.1038/s41598-025-34723-8
Received:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41598-025-34723-8
